12Mar2015 Antibiotic R&D Is Getting More Attention. Who’s Doing What? /Luke Timmerman/6/All, Drugs, FDA, Strategy12 Mar 2015 Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.